2024 Latin America Conference on Lung Cancer (LALCA) - Posters-PP01.44: Budget Impact Analysis for the Colombian Healthcare System of Participating in Sponsored Clinical Trials in Cancer: a Real-World Evidence Approach

PP01.44: Budget Impact Analysis for the Colombian Healthcare System of Participating in Sponsored Clinical Trials in Cancer: a Real-World Evidence Approach

Back to course

Pdf Summary

The study examines the budget impact of including cancer patients in sponsored phase III clinical trials on the Colombian healthcare system, focusing on hematology and oncology cases. Clinical trials represent an opportunity for significant economic savings in drug acquisition and follow-up costs, particularly for low- and middle-income countries. The research utilizes real-world data from the Luis Carlos Sarmiento Angulo Cancer Treatment and Research Center to assess the financial implications.<br /><br />An estimated 7,703 Colombian patients could potentially participate in clinical trials in 2023, with anticipated savings of USD 244.2 million per year and USD 1.22 billion over five years. The savings come from reduced costs per cancer type, with HER2-positive advanced breast cancer demanding the highest average annual cost per patient at USD 67,685. Conversely, advanced prostate cancer, while not the costliest, presents the largest potential enrollment opportunity due to its high prevalence, accounting for nearly half of the total eligible population.<br /><br />The study emphasizes that if 20% of eligible patients are enrolled, annual savings could amount to USD 48.8 million. Increasing enrollment rates by 20% annually could realize total potential savings by the fifth year. These savings enhance patient access to innovative treatments, improve clinical outcomes, and maintain long-term financial sustainability for the healthcare system.<br /><br />This budget impact analysis aligns with the Colombian Ministry of Health's Ten-Year Public Health Plan goals to reduce avoidable mortality and disability. Essentially, the study advocates for promoting participation in clinical trials, benefiting both patients and the healthcare system through economic advantages and improved health outcomes.

Asset Subtitle

Natalia Sánchez

Keywords

clinical trials

Colombian healthcare system

cancer patients

hematology

oncology

economic savings

drug acquisition

real-world data

budget impact

patient enrollment